MedPath

Artificial Intelligence to StrategiCally Enhance Pulmonary Embolism Response Team Activation

Not Applicable
Withdrawn
Conditions
Pulmonary Embolism Subacute Massive
Interventions
Diagnostic Test: Walking test
Registration Number
NCT06246045
Lead Sponsor
University Hospitals Cleveland Medical Center
Brief Summary

Pulmonary embolism (PE) remains a high mortality and morbidity disease state. The investigators have previously shown that use of a Pulmonary Embolism Response Team (PERT) can improve overall readmission, bleeding, and mortality outcomes. Unfortunately, PERT may still be underutilized from a national standpoint and may not be readily available in underserved areas.

The use of artificial intelligence (AI) may help streamline and systematically ensure unbiased mechanism for activation of PERT for discussion of patients with siginficant clot burden and hemodynamic abnormalities. AI algorithms have been FDA approved for use of triage of the PE patient. The institutional PERT program will adapt the use of an AI algorithm for activation as routine care; the efficiency of activation will be compared to our retrospective historical comparison for efficiency and appropriateness of activation.

The active phase of the study is designed to further differentiate between patients who are considered to be intermediate-high risk category but yet do not clearly qualify for invasive therapy (catheter-directed therapy, systemic thrombolysis, or invasive hemodynamic support). These patients will undergo walking test to further understand noninvasive hemodynamic compromise and undergo 2:1 randomization to early-invasive strategy versus mtranditional medical therapy.

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
390
Inclusion Criteria
  • Patients obtaining a CT at University Hospitals found to have a pulmonary embolism with evidence of right ventricular strain (RV:LV > 0.9) along with an abnormal vital sign (HR > 110 bpm, RR > 30/min, SBP < 100 mmHg, or O2 saturation < 90%)
  • Patients undergoing PERT discussion as deemed appropriate by the provider
Exclusion Criteria
  • Age <18
  • Pregnant patients. Women of childbearing age will be asked if they are pregnant before enrollment. No formal pregnancy test will be performed as a part of this study. If a patient does require invasive intervention, as part of the routine procedure for cardiac catheterization laboratory, women of childbearing age will either undergo pregnancy testing or opt-out per their own discretion
  • Patients unable to perform 6MWT (e.g., lack of one or both legs) will not be included in the randomization. They will be included in the observation for routine treatment

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Early-Invasive StrategyWalking testPatients who do not clearly qualify for early intervention (including catheter-directed therapies, systemic thrombolysis, or invasive hemodynamic support) based on assessment by PERT members, will undergo walk testing on the first day of admission. If the subject meets criteria based on pre-specified hemodynamic changes, then the patient will be randomized in a 2:1 fashion to early invasive strategy with catheter-directed therapies as treatment arm.
Traditional Medical TherapyWalking testPatients who do not clearly qualify for early intervention (including catheter-directed therapies, systemic thrombolysis, or invasive hemodynamic support) based on assessment by PERT members, will undergo walk testing on the first day of admission. If the subject meets criteria based on pre-specified hemodynamic changes, then the patient will be randomized (2:1, treatment to control) to traditional routine care with medical therapy.
Primary Outcome Measures
NameTimeMethod
Time-to-activation3 days

Activation of PERT from time of CT scan to call; compared to historical control

Secondary Outcome Measures
NameTimeMethod
Length of stay30 days

Total length of hospital stay

Change in quality of life as measured by PEmb QoLBaseline, 30 days, 90 days

PEmb-QoL summary score (0-100, higher score indicate worse outcome)

6-minute walk test (6MWT)6 minutes

The distance (meter) and walking speed (meter per seconds) in a 6-minute walk test.

Trial Locations

Locations (1)

University Hospitals Cleveland Medical Center

🇺🇸

Cleveland, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath